Termination of Voting Agreement by NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc. has filed an amendment to its Schedule 13D to disclose the termination of a voting agreement. The agreement, originally dated August 19, 2025, involved NovaBay Pharmaceuticals, Mr. David Elliot Lazar, and a group of stockholders including Jad Fakhry and entities associated with Poplar Point Capital. The termination is effective immediately upon the approval of the agreement. The filing includes an Irrevocable Notice of Termination, which states that all rights and obligations under the voting agreement, including all grants of proxy, will cease upon termination. The notice also specifies that the termination cannot be revoked, modified, or amended without the prior written consent of all parties involved. The filing is signed by David Lazar, CEO of NovaBay Pharmaceuticals.